Skip to main content

Recent Transactions

Our latest work in the life sciences and high-tech fields.

Our work

6 Dimensions Capital Logo

6 Dimensions Capital

VC Investments

Equity investments in multiple portfolio companies, including Hibercell

Website
Puma Biotechnology, Inc. Logo

Puma Biotechnology, Inc.

Clinical Trial

CRO and Site Agreements for an Open-Label, Phase 2 Study with 30 Sites in 9 Countries exploring the efficiency of Neratinib on Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations Or EGFR Gene Amplification

See Study
Vizgen, Inc. Logo

Vizgen, Inc.

Series C Financing

Vizgen raises Series C equity funding led by Blue Water Life Science Advisors, LLC, ARCH Venture Fund X, L.P. and other existing investors

Press Release
Vernal Biosciences, Inc. Logo

Vernal Biosciences, Inc.

Series A Financing

Vernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership

Press Release
Artax Biopharma, Inc. Logo

Artax Biopharma, Inc. + Advent Life Sciences Fund II LP

Series B Financing (Series B4)

Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly

Press Release
Dianthus Therapeutics, Inc. Logo

Dianthus Therapeutics, Inc.

Series A Financing

Dianthis raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors

Press Release
Summation Bio, Inc. Logo

Summation Bio, Inc.

Series A Financing

Summation Bio raises Series A equity funding led by RA Capital Healthcare Fund, L.P., RA Capital NEXUS Fund, L.P., RA Capital NEXUS Fund III, L.P., Blackwell Partners LLC and other existing investors

ONK Therapeutics Limited Logo

ONK Therapeutics Limited + Intellia Therapeutics, Inc.

License, Collaboration and Option Agreement

License, Collaboration and Option Agreement to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M per product plus royalties

Press Release
DermBiont, Inc. Logo

DermBiont, Inc. + Chromaderm, Inc.

Private Company Acquisition

DermBiont acquires Chromaderm, Inc.

Press Release
Sirtex Technology Pty Ltd Logo

Sirtex Technology Pty Ltd

Clinical Trial

CRO and Site Agreements for a pivotal device study with 15 US sites to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC (Barcelona clinic liver cancer (BCLC) stage A, BCLC stage B1 and BCLC stage B2)

See Study
IDEAYA Biosciences, Inc. Logo

IDEAYA Biosciences, Inc.

Clinical Trial

CRO and Site Agreements for a Phase I Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of IDE397 (MAT2A inhibitor) in patients with advanced solid tumors

See Study
Vizgen, Inc. Logo

Vizgen, Inc.

Series B Financing

Vizgen raises Series B equity funding from Northpond Ventures LP, ARCH Venture Fund X, L.P., Novalis LifeSciences LLC, Tao Capital Management, Pura Vida Investments and other current investors

Press Release
5AM Venture Management LLC Logo

5AM Venture Management LLC + Entrada Therapeutics, Inc.

Series B Financing

Need to remove?

Press Release
Global Alliance for TB Drug Development Logo

Global Alliance for TB Drug Development + GlaxoSmithKline

Research and Development Collaboration Agreement

Amended and Restatement of Research and Development Collaboration Agreement with GSK to identify and advance novel chemical entities for the potential treatment of TB as well as non-tuberculosis mycobacterial infections

Press Release
FOG Pharmaceuticals, Inc. Logo

FOG Pharmaceuticals, Inc.

Series C Preferred Financing

FogPharma raises Series C equity funding led by venBio Partners, Cormorant Asset Management, Farallon Capital Mgmt., Invus, funds/accounts advised by T. Rowe Price, HBM Healthcare Investments, Casdin Capital and PagsGroup, w/participation from investors GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital

Press Release
GV Management Company, LLC Logo

GV Management Company, LLC + Hyperfine Research

Series D Financing

Faber has assisted GV in Hyperfine Research’s $90M Series D Financing

Press Release
page 1 / 5

Here’s how we can help you

This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.